KRAS and cancer: Analyzing induced exogenous Cas9 activity in 1601 cancer cell lines from DepMap (1375 and 226 KRAS WT and mutant, respectively)10, we find that, like p53, Cas9 activity is significantly higher in KRAS-mutant cells than in KRAS WT cells (P = 2.9E−05, Wilcoxon Rank-Sum test, Fig. 6d; see the “Methods” section).